Comparing of the First Electrocardiographic Variables in Patients with Newly Diagnosed COVID-19 with Healthy Men Volunteer: A Systematic Review and Meta-Analysis

Mahdieh ARIAN\(^1\), *Ali VALINEJADI\(^2\), Farveh VAKILIAN\(^3\)

1. Faculty of Nursing and Midwifery, Semnan University of Medical Sciences, Semnan, Iran
2. Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran
3. Department of Cardiology, Preventive Atherosclerotic Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

*Corresponding Author: Email: valinejadi.a@semums.ac.ir

(Received 22 Oct 2020; accepted 11 Nov 2020)

Abstract
Background: We aimed to report the findings of the first Electrocardiography (ECG), before therapy initiation and receiving medication in COVID-19 patients, and to compare them with the ECG findings of healthy men.

Methods: A comprehensive and regular search was performed through the keywords (“Electrocardiographic” OR “ECG” OR “COVID-19” OR “Coronavirus Disease 2019”) without time and language restrictions in the Web of Science, Scopus, ProQuest, Cochrane Library, Science Direct, Medline, PubMed and Google Scholar. After evaluating the quality and reviewing the biases, 27 studies were finally enrolled.

Results: In 27 studies with a total number of 3994 COVID-19 patients, and mean age of 62.7 yr, 1993 subjects were male. The most common type of arrhythmia in them, especially in severe and critical cases, was 7% based on 10 studies (Atrial Fibrillation); while in 7 studies, QTc interval prolong (≥ 460 msec) was 15% and in 5 studies, QTc interval prolong (≥ 500 msec) was 18%. In COVID-19 patients at the time of admission and healthy men, HR (b per / min) was 85, 61.7 and PR interval (msec) was 285.4, 156 and QRS duration (msec) was 95, 94.3 and QT (msec) was 380.384.1 and QTc (msec) (Bazett's formula) was 437, 387.1, respectively. In most cases, the variables were higher for COVID-19 patients.

Conclusion: ECG abnormalities at the time of admission and prior to the initiation of medication that cause arrhythmic may have a clinically substantial effect on the course of the disease and confirm the effect of COVID-19 on increased cardiovascular risk in long-term.

Keywords: Electrocardiographic; COVID-19; Arrhythmia; Heart; Meta-analysis

Introduction

Coronavirus Disease 2019 (COVID-19) is a clinical manifestation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) with a high mortality rate. The clinical course of the infection is characterized by respiratory symptoms including fever, cough, and fatigue, and may progress to pneumonia, Acute Respiratory Distress Syndrome (ARDS), and shock (1). Adverse effects of COVID-19 on cardiovascular disease with acute cardiovascular syndrome have been described as decompensated heart failure, acute coronary syndromes and myocarditis, which increase mortality (2).
Therefore, it is important to identify prognosis-related markers that assist physicians in rapidly triaging and conduct clinical decision-making. Electrocardiography (ECG) is a fully accessible diagnostic test performed quickly without large numbers of personnel being exposed to SARS-CoV2. ECG has been shown to increase prognostic value in population-based studies and among patients with a variety of underlying cardiovascular diseases, including hypertension (3). Therefore, it is of special seriousness during the current epidemic.

Therefore, the objective of the present systematic review and meta-analysis was to report the findings of the first ECG, before starting treatment and prior to receiving medication in Covid-19 patients, and to compare them with the ECG findings of healthy men.

Methods

Objective

The objective of the present meta-analysis is to report the findings of the first ECG, prior to treatment initiation and before receiving medication in COVID-19 patients, and to compare them with the ECG findings of healthy men. The present study was conducted based on the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) (4) and it has the ethics code (IR.SEMUMS.REC.1399.230).

Components of structured question (PICO) were population (P): newly diagnosed patients with COVID-19; and intervention (I): not required; comparison (C): with healthy men; outcome (O): findings of the first ECG before treatment initiation and receiving medication. The results of this meta-analysis in COVID-19 patients were compared to the results of the study in healthy men volunteer (5).

Search Strategy

A comprehensive and regular search was performed with the keywords (“Electrocardiographic” OR “ECG” OR; “COVID-19” OR “Corona-virus Disease 2019”) without time and language restrictions in the following databases: Web of Science, Scopus, ProQuest, Cochrane Library, Science Direct, Medline, PubMed and Google Scholar.

Eligible Criteria

Retrospective, prospective, randomized, and nationwide studies reported the first ECG findings of COVID-19 patients before receiving any medication were included in this review; and pediatric studies or studies that did not report the findings of the first ECG prior to treatment in these patients, and case report studies were excluded.

Selection Procedure

Out of 589 searches, 149 were excluded due to duplication. Title and abstract of 440 studies were reviewed. Texts that did not contain ECG or COVID-19 related findings in their titles and abstracts were also excluded in 358 cases. Eighty-two full-text articles were reviewed by two researchers based on inclusion and exclusion criteria. Fifty articles were excluded due to lack of detailed reporting of ECG findings and five were excluded due to ECG findings reported after receiving medication. Finally, 27 articles were selected and included in quality evaluation stage (Fig. 1).

Quality Assessment

To evaluate the critical evaluation of studies, a 5-item checklist was used based on JBI Critical Appraisal Checklist for Case Control Studies and longitudinal cohort, or cross-sectional Studies Reporting Prevalence Data (6). The two authors independently reviewed each study based on the criteria in these checklists with the options of “Yes”, “No”, and “Unclear”. For each item “Yes”, had a score of two, “Unclear” had a score of one and “No” had no score. Total scores of each study were considered as total scores. Quality classification of studies in this 5-item checklist was high (7-10), Moderate (3-6), and Weak (3>). Figure 2 shows a review of the biases of the reported studies.
Fig. 1: PRISMA flow diagram

Fig. 2: Review of the biases of the reported studies
Data Extraction
Based on the inclusion and exclusion criteria, the two researchers independently reviewed the title and abstract of the studies. Whenever there was disagreement between them in selecting the articles, the third person, as a judge, resolved the disagreement through discourse. Variables were extracted from the study, including the name of the first author, publication year, age, sample size, BMI, and findings of the first ECG at the time of admission and prior to drug administration.

Data Synthesis and Statistical Analysis
Mean or Prevalence was reported by confidence interval (95% CI). Besides, the randomized model was reported by 95% CI. \( P \) value < 0.05 was considered statistically significant. The Q statistic and the \( I^2 \) index were used to assess the heterogeneity of the studies. The \( I^2 \) index was used due to its accuracy to compensate for the lack of power (the Q statistic) in small sample sizes or increase the power in large sample sizes. In the \( I^2 \) index, a value of less than 50% indicated low variance between studies and a fixed effect model and the inverse variance method were used. Otherwise I-V heterogeneity method was used (7). Studies data were entered into comprehensive meta-analysis and -5RecMan softwares and data were analyzed. The radar chart was used to compare the ECG findings of COVID-19 patients and healthy men.

Results

Characteristics of the Included Studies
In 27 studies published in 2020, a total of 3994 COVID-19 patients were studied, of which 1993 were male. The mean age of patients in 26 studies was 62.7 yr with 95% CI: 0.51-0.66, and interquartile range (IQR) was 18.44-23.5. The mean BMI of patients in 13 studies was 28 (Kg/m2), while 95% CI was 27.2-28.7. The sample size of the studies ranged from six to 756. Other information related to selected studies is listed in Table 1.

Table 1: Basic characteristics of the included studies in the meta-analysis

| Reference | Time of patients presented to hospital | country   | Type of study            | n | Age (yr) M | sd | Male% |
|-----------|----------------------------------------|-----------|--------------------------|---|------------|----|-------|
| (8)       | 01/06/2020 to 02/20/2020               | China     | Retrospective cohort      | 112 | 65.0       | (49-71) | 57(50.9) |
| (9) All   | 01/27/2020 to 02/28/2020               | China     | Cross-sectional          | 54  | 57.6       | 11  | 36(66) |
| (9)Severe group |                     | China     | Cross-sectional          | 39  | 56.1       | 13.5| 27(69.2) |
| (9)Critical group |              | China     | Cross-sectional          | 15  | 61.7       | 9.6 | 9(60)   |
| (10)      | 01/NR/2020 to 12/NR/2020               | France    | Observational            | 100 | 67         | 7   | 59(59) |
| (11)      | 02/01/2020 to 04/04/2020               | USA       | Case series              | 98  | 62.3       | 17  | 60(61) |
| (12)      | 02/13/2020 to 04/05/2020               | USA       | Observational            | 105 | 67         | 15  | 58(55.2) |
| (13)      | 02/30/2020 to 03/30/2020               | Iran      | Prospective cohort       | 119 | 60.52      | 13.45| 78(65.5) |
| (13)Survivedgroup |                   | Iran      | Prospective cohort       | 107 | 59.8       | 13  | 71(66.4) |
| (13)Diedgroup  |                       | Iran      | Prospective cohort       | 12  | 67.4       | 16  | 7(58.3) |
| (14)All   | 02/NR/2020 to 03/NR/2020               | Germany   | Prospective              | 123 | 68         | 15  | 77(62.6) |
| (14)Survivedgroup |                   | Germany   | Prospective              | 107 | 67         | 15  | 65(60.7) |
| (14)Diedgroup |                        | Germany   | Prospective              | 16  | 73         | 16  | 12(75.0) |

Available at:  http://ijph.tums.ac.ir
Table 2 demonstrates the results of pooled mean and prevalence with confidence intervals for the first ECG findings in COVID-19 patients based on a randomized model. Accordingly, the pooled mean for HR (b per / min) in 15 studies was 85.5 (msec) and 95% CI was 90-81; it was 95 (msec) for QRS durationin (msec) in 7 studies with 95% CI of 93-97; while QT (msec) in 5 studies was 380 (msec) with 95% CI of 339-422; QT (msec) according to Bazett's formula in 21 studies was 437 (msec) with 95% CI of 427-447. In seven studies, QTc interval prolong (≥ 460 msec) was 15% with 95% CI of 0.09-0.24; and in 5 studies, QTc interval prolong (≥ 500 msec) was 18% with

| Study No. | Date Range          | Country | Study Type                  | HR (b/min) | HR 95% CI | QT (msec) | QT 95% CI | QTc (msec) | QTc 95% CI |
|-----------|---------------------|---------|-----------------------------|------------|-----------|-----------|-----------|------------|------------|
| (15)      | 03/01/2020 to 03/23/2020 | USA     | Retrospective cohort       | 201        | 58.5      | 9.1       | 115       | (57.2)     |
| (16)      | 03/01/2020 to 04/15/2020 | USA     | Retrospective cohort       | 6          | 57        | 10.6      | 2         | (33.3)     |
| (3)       | 03/03/2020 to 04/09/2020 | USA     | Retrospective cohort       | 756        | 63.3      | 16.0      | 278       | (63.2)     |
| (3)       | Survived group      |         |                             |            |           |           |           |            |            |
| (3)       | Died group          |         |                             |            |           |           |           |            |            |
| (17)      | 03/08/2020 to 03/27/2020 | Netherlands | Retrospective cohort | 95         | 65        | (18–91)   | 63        | (66)       |
| (18)      | 03/09/2020 to 03/15/2020 | Italy   |                             | 113        | 68        | (61–74)   | 85        | (75)       |
| (19)      | 03/10/2020 to 04/22/2020 | Netherlands | Retrospective cohort | 397        | 67.8      | 12.5      | 262       | (66)       |
| (20)      | All                 |         |                             | 224        | 65        | 7         | 127       | (56.7)     |
| (20)      | ICU group           |         |                             | 57         | 67        | [58, 76]  | 31(51)    |            |
| (20)      | No ICU group        |         |                             | 167        | 65        | [51, 77]  | 96(57.5)  |            |
| (2)       | 03/15/2020 to 04/15/2020 | Italy   | Cross-sectional             | 50         | 64        | 15        | 36        | (72.2)     |
| (21)      | 03/17/2020 to 04/30/2020 | Indonesia | Observational case series | 30         | 53.9      | 16.4      | 16        | (53.3)     |
| (22)      | 03/18/2020 to 03/225/2020 | France  |                             | 50         | 68        | 53.81     | 28(55.2)  |            |
| (23)      | Case group          |         |                             | 75         | 55.5      | 17.1      | 39        | (52)       |
| (23)      | Control group       |         |                             | 75         | 50.2      | 16.6      | 41        | (54)       |
| (24)      | 03/23/2020 to 04/05/2020 | Brazil  | RCT                         | 81         | 51.1      | 13.9      | 61(86.1)  |            |
| (25)      | 03/24/2020 to 04/20/2020 | France  | Prospective observational   | 73         | 62        | 14        | 49(67)    |            |
| (26)      | 03/28/2020 to 04/20/2020 | New Haven | Cross-sectional             | 524        | 68.2      | 15.2      | 64(62.1)  |            |
| (27)      | 03/31/2020 to 04/16/2020 | Turkey  | Retrospective observational | 109        | 57.3      | 14.4      | 48        | (44)       |
| (28)      | Case group          |         |                             | 51         | 49.2      | 16.7      | 29(57)    |            |
| (28)      | Control group       |         |                             |            |           |           |           |            |            |
| (29)      | Case group          |         |                             |            |           |           |           |            |            |
| (29)      | Control group       |         |                             |            |           |           |           |            |            |
| (30)      | 03/NR/2020 to 04/NR/2020 | Italy   | Case-control                | 40         | 47.9      | 14.9      | 26(65)    |            |
| (31)      | 04/NR/2020          | USA     | Cohort                      | 22         | 64        | (56–70)   | 18(82)    |            |
| (31)      | 04/NR/2020          | USA     | Retrospective               | 34         | 64        | (56–70)   | 18(82)    |            |
| (32)      | 05/25/2020 Accepted | Connecticut | Retrospective               | 91         | 62.7      | 15.1      | 60(56)    |            |
95% CI of 0.012-0.8. In four studies, premature beat was 15% and 95% CI was 0.07-0.27. In 10 studies, atrial fibrillation was 7% and 95% CI was 0.05-0.9.

Table 2: Meta-analysis outcomes (random-effects model).a

| Variable                              | Number of Studies | Mean / (Se) | 95% CI | n   | Qb | I²c | t²d | Heterogeneity P-value | Egger P-value |
|---------------------------------------|-------------------|-------------|--------|-----|----|-----|-----|-----------------------|--------------|
| Age (yr)                              | 26                | 62.5 (0.7)  | 61-64  | 3910| 567| 95.5 | 12.1| <0.001                | <0.001       |
| Male                                  | 26                | 0.6         | 0.51-0.66 | 1993/39 10| 489 | 94.9 | 0.6 | <0.001                | 0.047        |
| BMI (Kg/m2)                           | 13                | 28 (0.4)    | 27.2-28.7 | 1979| 118| 90  | 1.55| <0.001                | 0.82         |
| HR (b per/min)                        | 15                | 85.5 (2.3)  | 81-90  | 2194| 662| 98  | 78.6| <0.001                | 0.68         |
| PR interval (msec)                    | 5                 | 258.4 (30)  | 201-315 | 314 | 1219 | 99.6 | 418 | <0.001                | 0.049        |
| QRS duration (msec)                   | 7                 | 95 (0.9)    | 93-97  | 1000| 18.8| 68  | 3.5  | <0.001                | 0.74         |
| QT (msec)                             | 5                 | 380 (21.2)  | 339-422 | 857 | 1377| 99.7 | 224 | <0.001                | 0.97         |
| QTc(msec) (Bazett's formula)          | 21                | 437.39 (5)  | 427-447 | 3355| 5201| 99.6 | 520  | <0.001                | 0.62         |
| QTc interval Prolong (≥ 460 msec)     | 7                 | 0.15        | 0.09-0.24 | 159/954 | 29 | 79.4 | 0.34 | <0.001                | 0.41         |
| QTc interval Prolong (≥ 500 msec)     | 5                 | 0.18        | 0.012-0.8 | 114/344 8| 124.1 | 96.78 | 10.4 | <0.001                | 0.4          |
| Sinus Tachycardia                     | 5                 | 0.34        | 0.17-0.56 | 125/408 | 55 | 92.55 | 0.93 | <0.001                | 0.85         |
| Sinus Bradycardia                     | 3                 | 0.05        | 0.02-0.13 | 14/264 | 5.6 | 64.43 | 0.52 | <0.001                | 0.22         |
| AF                                    | 10                | 0.07        | 0.05-0.9 | 113/178 2| 16.3 | 44.82 | 0.09 | <0.001                | 0.94         |
| VT                                    | 2                 | 0.04        | 0.15-0.09 | 5/145 | 1.07 | 6.6  | 0.03 | 0.3                   | -            |
| Premature beat                        | 4                 | 0.15        | 0.07-0.27 | 144/113 4| 42  | 93   | 0.6  | <0.001                | 0.8          |
| PAC                                   | 2                 | 0.09        | 0.06-0.15 | 73/875 | 3.2 | 68.7 | 0.2  | 0.07                   | -            |
| PVC                                   | 2                 | 0.08        | 0.01-0.35 | 48/875 | 35.8 | 97   | 2.4  | <0.001                | -            |
| AVB                                   | 3                 | 0.02        | 0.017-0.04 | 23/929 | 1.56 | 0.00  | 0.00 | <0.001                | 0.71         |
| LBBB                                  | 5                 | 0.025       | 0.013-0.05 | 27/1312 | 10.35 | 61.36 | 0.33 | 0.035                | 0.9          |
| RBBB                                  | 7                 | 0.06        | 0.05-0.08 | 96/1435 | 6.8 | 12.68 | 0.07 | 0.33                   | 0.06         |
| LAD                                   | 2                 | 0.27        | 0.08-0.6  | 24/125 | 3.2 | 69.4 | 0.82 | 0.07                   | -            |
| RAD                                   | 2                 | 0.07        | 0.04-0.13 | 9/125 | 0.78 | 0.00  | 0.00 | 0.37                   | -            |
| LAE                                   | 2                 | 0.27        | 0.06-0.7  | 25/137 | 11.7 | 91.5 | 1.6  | 0.001                  | -            |
| RAE                                   | 2                 | 0.18        | 0.12-0.25 | 25/137 | 0.7 | 0.00  | 0.00 | 0.4                   | -            |
| LVH                                   | 2                 | 0.14        | 0.07-0.23 | 118/774 | 1.2 | 17   | 0.11 | 0.27                   | -            |
| RVH                                   | 2                 | 0.04        | 0.028-0.05 | 31/774 | 0.11| 0.00  | 0.00 | 0.73                   | -            |
In 7 studies QTc interval prolong (≥ 460 msec) was 15% and 95% CI was 0.09-0.24. In 5 studies, QTc interval prolong (≥ 500 msec) was 18% and 95% CI was 0.012-0.8. In 5 studies, Sinus Tachycardia was 34% and 95% CI was 0.17-0.56. In 5 studies, T inverted was 15% and 95% CI was 0.09-0.25. In 7 studies, ST-T abnormalities was 22% and 95% CI was 0.11-0.38. In 7 studies, RBBB was 6% and 95% CI was 0.05-0.08. In 5 studies, LBBB was 2.5% and 95% CI was 0.013-0.05. Figure 3 depicts the details of pooled mean scores and graphical funnel plot for QTc (msec) based on Bazett's formula in COVID-19 patients before therapy initiation.

### Table 1: Percentage of QTc interval prolong (≥ 460 msec)

| Study or Subgroup | Mean | SE  | Weight | IV Random, 95% CI |
|-------------------|------|-----|--------|------------------|
| Janghel et al., 2020 | 42.9 | 0.7 | 4.09 | 42.90 [42.10, 43.70] |
| Brishchikov et al., 2020 | 43.5 | 0.3 | 4.68 | 43.50 [42.91, 44.08] |
| Enke et al., 2020 | 42.4 | 0.2 | 4.03 | 42.40 [41.92, 42.88] |
| Bury et al., 2020 | 43.6 | 0.1 | 4.78 | 43.60 [43.26, 44.00] |
| Cherny et al., 2020 (a) | 42.7 | 0.9 | 4.09 | 42.70 [41.45, 44.09] |
| Cherny et al., 2020 (b) | 43.9 | 0.8 | 4.05 | 43.90 [43.47, 44.62] |
| Cipriani et al., 2020 | 43.6 | 1.6 | 4.06 | 43.60 [42.03, 45.19] |
| Goyan et al., 2020 | 43.1 | 0.7 | 4.22 | 43.10 [42.08, 44.15] |
| Hala et al., 2020 | 43.9 | 0.6 | 4.09 | 43.90 [43.82, 44.18] |
| Jain et al., 2020 | 50.7 | 1.2 | 4.09 | 50.70 [50.46, 50.95] |
| Maraj et al., 2020 | 43.7 | 2.6 | 4.06 | 43.70 [43.01, 44.41] |
| McCullough et al., 2020 | 44.9 | 6.2 | 4.78 | 44.90 [44.01, 45.79] |
| Moschin et al., 2020 | 43.2 | 0.5 | 4.09 | 43.20 [43.03, 43.38] |
| Ozbar et al., 2020 | 410.3 | 3.3 | 4.09 | 410.30 [409.58, 411.67] |
| Rivas-Medrano et al., 2020 | 448.3 | 3.3 | 4.09 | 448.30 [445.72, 451.81] |
| Roff et al., 2020 | 445.3 | 3.9 | 4.09 | 445.30 [442.09, 448.58] |
| Saleh et al., 2020 | 430.5 | 1.7 | 4.09 | 430.50 [426.41, 444.63] |
| Skolier et al., 2020 | 448.4 | 1.7 | 4.09 | 448.40 [444.07, 452.73] |
| van den et al., 2020 | 432.4 | 4.0 | 4.09 | 432.40 [422.40, 442.50] |
| Vaezian et al., 2020 | 450.7 | 0.7 | 4.09 | 450.70 [450.53, 450.87] |
| Yavari et al., 2020 | 411.4 | 2.0 | 4.09 | 411.40 [406.09, 416.10] |
| Total (95% CI) | 100.0% | 435.69 [435.69, 446.41] |

Heterogeneity: τ² = 5.7675; χ² = 63.1537; df = 20 (P < 0.00001); I² = 100%

Test for overall effect: Z = 81.96 (P < 0.00001)

Fig. 3: Impact of COVID-19 on QTc (msec) before initiation of therapy (Forest plot & Funnel plot)
**Electrocardiographic Features of COVID-19 Patients and Outcome**

The radar chart (Fig. 4) compares the findings of the first ECG of COVID-19 patients before therapy initiation with the findings of a meta-analysis related to the ECG findings of healthy male volunteers before receiving any intervention. The most changes were related to PR interval (msec), QTc (msec) (Bazett’s formula) and HR (b per / min).

![Radar Chart Comparison](image)

**Fig. 4:** Use of radar chart to compare the ECG features in patients with COVID-19 with healthy male volunteers

In two studies, there was no significant difference between the survived and died groups in the standardized mean QTc (msec) \((P = 0.36)\) with 95% CI of \(-0.30, 0.11\). In three studies, there was no significant difference between the survived and died groups in the standardized mean HR (b per / min) \((P = 0.92)\) with 95% CI of \(-0.31, 0.27\) (Fig. 5-A). In three case-control studies, there was no significant difference between the control group and COVID-19 group in the standardized mean QTc (msec) \((P = 0.08)\) with 95% CI of \(-0.09, 1.67\) and HR (b per / min) \((P = 0.15)\) with 95% CI of \(-0.48, 3.06\) (Fig. 5-B).

**Publication Bias Assessment**

In the present study, publication bias was reported by the Egger test and the results are shown in Table 2. Moreover, graphical funnel plots were symmetrical in most zones and did not show bias. Funnel plot for QTc (msec) is shown in Fig. 3.
Discussion

Despite the important role of the ECG in diagnosing the complications of COVID-19 in the acute phase, unfortunately there is no detailed study on the characteristics of the ECG and their changes during the hospitalization of COVID-19 patients before starting pharmacotherapy. In this regard, the researchers of the present study analyzed the data of 27 studies on the findings of the first ECG of COVID-19 patients who were hospitalized and had not yet received medical treatment. Finally, they have provided some of the key issues that are worth mentioning.

ECG abnormalities at the time of hospitalization due to COVID-19 entailed a wide range of cardiovascular complications including acute coronary syndrome, arrhythmic disorders and ST-T ischemic changes, so that based on the data analysis from five studies T inverted was 15% and according to data analysis in seven studies ST-T abnormalities was 22%. Cardiac arrhythmias in COVID-19 patients were similar to those in SARS patients in 2003 (33). Analysis of five studies showed that Sinus Tachycardia with 34% is the most common type of arrhythmia in COVID-19 patients, especially in severe and critical cases. In ten studies, atrial fibrillation was 7%. Thus, it is possible that atrial fibrillation in COVID-19 is associated with increased systemic
inflammation, fever, hypoxia, and adrenergic tone (2). However, involvement of epicardial adipose tissue during SARS-CoV-2 infection is associated with atrial electrical regeneration and the progression of atrial fibrillation (34). In four studies, premature beat was 15%. Given the before therapy reviews, the inflammatory response caused by COVID-19 may be more effective on the higher prevalence of premature atrial and ventricular beats than on medications (29).

Altogether, these findings reinforce the recommendation to accurately reassess and evaluate therapy options of anticoagulants, balancing the risk of thromboembolic and bleeding risk. In COVID-19 patients, hydroxychloroquine and azithromycin are at risk for QT prolongation. However, the present study analyzed the ECG findings before starting treatment, according to which in seven studies, QTc interval prolong (≥ 460 msec) was 15% and in five studies, QTc interval prolong (≥ 500 msec) was 18%. Due to the lack of medication use before ECG, QT prolongation may be due to monogenetic stress or other undetected hereditary lesions (35); and in several studies, the main reason for the prolongation of QT has been mentioned to be the use of arrhythmogenic drugs. However, since the initial ECG of COVID-19 patient shows a relative QT prolongation, further studies are needed to assess the interval. In some previous studies, the details of the time of diagnosis before hospitalization were not specified, and just the first ECG was recorded at the time of admission for the patients diagnosed with COVID-19. The lack of details of detection time may have led to some details of the treatment not being reported, and patients may have been taking medication before being admitted to the hospital, but this has not been mentioned in the articles.

Data analysis showed that in COVID-19 patients at the admission time and in healthy men, HR (b per / min) was 85, 61.7; PR interval (msec) was 285.4, 156; QRS duration (msec) was 95, 94.3; QT (msec) was 380, 384.1; and QTc (msec) (Bazett's formula) was 437, 387.1, respectively. In most cases for COVID-19 patients, the variables were higher, possibly due to changes in autonomic tone, cardiopulmonary or peripheral deconditioning, and myocardial injury. Cardiac arrhythmias and ECG changes in COVID-19 patients before treatment compared to healthy men can occur due to myocardial ischemia, heart failure, increased catecholamine exposure, electrolyte disturbances, scar formation, hypoxia, autonomic dysfunction, and inflammation. Re-entry and acquired automaticity may initiate arrhythmogenesis at the cellular level (36). Systemic inflammation has significant effects on arrhythmogenesis. Systemic inflammation plays a key role in the development of arrhythmias by reducing the arrhythmogenic threshold in patients prone to arrhythmias.

Conclusion

In particular, COVID-19 is associated with complete heart block, acute coronary syndromes, myocarditis, decompensated heart failure, and pulmonary embolism. These findings support the notion that ECG abnormalities at the time of admission and prior to the initiation of arrhythmic medication may have a clinically substantial effect on the course of the disease and confirm the effect of COVID-19 on increased cardiovascular risk in long run.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

Research reported in this publication was supported from the Semnan University of Medical Sciences, Semnan, Iran.

Conflict of interest

The authors declare that there is no conflict of interest.
References

1. Cheng ZJ, Shan J (2020). 2019 Novel coronavirus: where we are and what we know. *Infection*, 48(2):155-163.
2. Angeli F, Spagnello A, De Ponti R, et al (2020). Electrocardiographic features of patients with COVID-19 pneumonia. *Eur J Intern Med*, 78:101-106.
3. McCullough SA, Goyal P, Krishnan U, et al (2020). Electrocardiographic Findings in Coronavirus Disease-19: Insights on Mortality and Underlying Myocardial Processes. *J Card Fail*, 26(7):626-632.
4. Moher D, Shamseer L, Clarke M, et al (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, 350:b6747.
5. Harris RI, Steare SE (2006). A meta-analysis of ECG data from healthy male volunteers: diurnal and intra-subject variability, and implications for planning ECG assessments and statistical analysis in clinical pharmacology studies. *Eur J Clin Pharmacol*, 62(11):893-903.
6. Moola S, Munn Z, Tufanaru C, et al (2020). Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis, JBI.
7. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. *Stat Med*, 21(11):1539-58.
8. Deng Q, Hu B, Zhang Y, et al (2020). Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. *Int J Cardiol*, 311:116-121.
9. Chen Q, Xu L, Dai Y, et al (2020). Cardiovascular manifestations in severe and critical patients with COVID-19. *Clin Cardiol*, 43:796-802.
10. Strik M, Caillol T, Ramirez FD, et al (2020). Validating QT-Interval Measurement Using the Apple Watch ECG to Enable Remote Monitoring During the COVID-19 Pandemic. *Circulation*, 142(4):416-418.
11. Ramireddy A, Chugh H, Reinier K, et al (2020). Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. *J Am Heart Assoc*, 9(12):e017144.
12. C Hsia B, Greige N, A Quiroz J, et al (2020). QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. *J Int Card Electrophysiol*, 1-9.
13. Pishgahi M, Yousefifard M, Safari S, Ghorbanpouryami F (2020). Electrocardiographic Findings of COVID-19 Patients and Their Correlation with Outcome; a Prospective Cohort Study. *Advanced Journal of Emergency Medicine*, In press.
14. Rath D, Petersen-Urbe Á, Avdiu A, et al (2020). Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection. *Clin Res Cardiol*, 109(12):1491-1499.
15. Saleh M, Gabriels J, Chang D, et al (2020). Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. *Circ Arrhythm Electrophysiol*, 13(6):e008662.
16. Gayam V, Konala VM, Naramala S, et al (2020). Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and *Mycoplasma pneumoniae* in the USA. *J Med Virol*, 2181-2187.
17. van den Broek MPH, Möhlmann JE, Abeln BGS, et al (2020). Chloroquine-induced QTc prolongation in COVID-19 patients. *Neth Heart J*, 28(7-8):406-409.
18. Moschini L, Loffi M, Regazzoni V, et al (2021). Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. *Heart Vessels*, 36(1):115-120.
19. Sinkeler FS, Berger FA, Muntinga HJ, Jansen MMPM (2020). The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine. *Neth Heart J*, 28(7-8):418-423.
20. Maeda T, Obata R, Rizk D, Kuno T (2020). The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City. *J Med Virol*, doi: 10.1002/jmv.26365.

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
21. Hafiz M, Icksan AG, Harlivasari AD, et al (2020). Clinical, Radiological Features and Outcome of COVID-19 patients in a Secondary Hospital in Jakarta, Indonesia. J Infect Dev Ctries, 14(7):750-757.

22. Voisin OMD, le Lor'ch EMD, Mahé AMD, et al (2020). Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection. Mayo Clin Proc, 95(8):1696-1700.

23. Yenerçağ M, Arslan U, Doğduş M, et al (2020). Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19. J Electrocardiol, 62:5-9.

24. Borba MGS, Val FFA, Sampaio VS, et al (2020). Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open, 3(4):e208857.

25. Bun SS, Taghji P, Courjon J, et al (2020). QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection. Clin Pharmacol Ther, 108(5):1090-1097.

26. Jain S, Workman V, Ganeshan R, Obasare ER, et al (2020). Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019. Heart Rhythm, 17(9): 1417–1422.

27. Bakhshaliyev N, Uluganyan M, Enhos A, et al (2020). The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. J Electrocardiol, 62:59-64.

28. Ozturk F, Karaduman M, Coldur R, 2020. Interpretation of arrhythmogenic effects of COVID-19 disease through ECG. Aging Male, 1-4.

29. Cipriani A, Zorzi A, Ceccato D, et al (2020). Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. International Journal of Cardiology, 316:280–284.

30. Chorin E, Dai M, Shulman E, et al (2020). The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med, 26(6):808-809.

31. Chorin E, Wadhwani I, Magnani S, et al (2020). QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm, 17(9):1425–1433.

32. Maraj I, Hummel JP, Taoutel R, et al (2020). Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin. J Cardiovas Electrophysiol, 31(8):1904-1907.

33. Yu CM, Wong RSM, Wu EB, et al (2006). Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J, 82(964):140–144.

34. Friedman DJ, Wang N, Meigs JB, et al (2014). Pericardial fat is associated with atrial conduction: the Framingham Heart Study. J Am Heart Assoc, 3(2):e000477.

35. Wu C-I, Postema PG, Arbelo E, et al (2020). SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm, 17:1456-1462.

36. Yalta T, Yalta K (2018). Systemic inflammation and arrhythmogenesis: a review of mechanistic and clinical perspectives. Angiology, 69(4):288-296.

Available at: http://ijph.tums.ac.ir